argenx SE commenced a tender offer for Forte Biosciences this morning, moving to acquire the San Diego dermatology developer after an 18-month clinical partnership around FB-102, Forte's investigational JAK1/TYK2 inhibitor for atopic dermatitis. The tender opens what most European biotech watchers estimate as a $90M-$120M takeout, though neither party disclosed cash consideration in this morning's filing. argenx carries $2.1B in cash as of September 2024, running a single-product revenue engine off VYVGART while scouting immunology adjacencies.
Forte shareholders receive all-cash consideration under the offer, with argenx setting a minimum tender condition at a majority of outstanding shares. The transaction bypasses a traditional merger proxy cycle, typical for small-cap biotechs where board-negotiated deals drag four to six months. Forte traded under $2.50 per share for most of 2024, valuing the company near $80M before today's announcement. argenx holds partnership rights to FB-102 in certain geographies, and pulling the full asset in-house collapses milestone payments into a single acquisition cost while eliminating future royalty obligations.
The move matters because argenx sits on VYVGART revenue approaching $2.8B annualized—myasthenia gravis and CIDP indications—but lacks a second commercial molecule. FB-102 entered Phase 2b trials in atopic dermatitis in late 2023, targeting a market already crowded with Dupixent, Rinvoq, and emerging IL-13 blockers. JAK1/TYK2 selectivity offers a theoretical safety margin over pan-JAK inhibitors, though real-world differentiation hinges on 24-week data not yet disclosed. If FB-102 clears pivotal trials by late 2026, argenx layers a second revenue stream into a portfolio otherwise concentrated in rare neuromuscular disease. The acquisition also answers the structural question facing every European biotech that hits $10B market cap: buy external innovation or die on internal R&D timelines.
Operators should track three events. First, tender expiration around mid-February 2025, assuming a 20-business-day window and no extension. Second, FB-102 Phase 2b topline data, likely disclosed in an argenx quarterly call within 90 days post-close if the study completes on schedule. Third, any FDA pre-IND meetings or SPA discussions for pivotal trials, which typically surface in 10-Q filings six months after acquisition close. argenx's development velocity—VYVGART went from Phase 3 start to approval in under four years—suggests an aggressive pivotal timeline if Phase 2b data clears a 50%+ EASI-75 response rate threshold.
Forte disappears into argenx's immunology pipeline before the dermatology asset even reaches proof-of-concept disclosure. That timing is the tell: argenx is paying for optionality before the market can price the data.